IS JAK2 V617F GENE POINT MUTATION A RISK FACTOR FOR BLEEDING OR THROMBOSIS IN PATIENTS WITH MYELOPROLIFERATIVE DISEASE?

Basit Öğe Kaydı
dc.contributor.authorBilgin, A. Ugur
dc.contributor.authorYildirim, M.
dc.date.accessioned2024-02-23T14:45:33Z
dc.date.available2024-02-23T14:45:33Z
dc.date.issued2012
dc.departmentNEÜen_US
dc.description.abstract[Abstract Not Availabe]en_US
dc.identifier.endpage642en_US
dc.identifier.issn0390-6078
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage642en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12452/17493
dc.identifier.volume97en_US
dc.identifier.wosWOS:000496830406150en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherFerrata Storti Foundationen_US
dc.relation.ispartofHaematologicaen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[Keyword Not Available]en_US
dc.titleIS JAK2 V617F GENE POINT MUTATION A RISK FACTOR FOR BLEEDING OR THROMBOSIS IN PATIENTS WITH MYELOPROLIFERATIVE DISEASE?en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu